In the middle of 2021, Sesen Bio started to gain momentum and significantly improved its price values. The most recent peak was on August 12 of 2021 when the price peaked at $4.91. After this peak, the stock has gradually declined. Today, the value stands at $0.8756. This is a $0.0482 and 5.82% loss since the previous close. Sesen Bio has added Eun Jang as Senior Director, Analytical Sciences, and Chèrie Kaefring as Director, Clinical Operations to its chemical, manufacturing, and control (CMC) and clinical development teams. The addition of those additional team members demonstrates Sesen Bio’s strong commitment to and ongoing competence in the development of Vicineum for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer.
- Infosys (INFY) Stock Gains Momentum With Excellent Q2 Performance
- Ballard Power Systems (BLDP) Stock Proceeds To Hit New Highs: What’s Going On?